195 related articles for article (PubMed ID: 11122801)
21. Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecologic diseases.
Guadagni F; Marth C; Zeimet AG; Ferroni P; Spila A; Abbolito R; Roselli M; Greiner JW; Schlom J
Am J Obstet Gynecol; 1994 Nov; 171(5):1183-91. PubMed ID: 7977516
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of the combined serum CA 125 and TPS during chemotherapy and before second-look laparotomy in epithelial ovarian cancer.
Senapad S; Neungton S; Thirapakawong C; Suphanit I; Hangsubcharoen M; Thamintorn K
Anticancer Res; 2000; 20(2B):1297-300. PubMed ID: 10810438
[TBL] [Abstract][Full Text] [Related]
23. Elevated ovarian cancer marker (CA-125) in cirrhotic patients with intractable ascites.
Zamir D; Jarchovsky J; Singer C; Weiner P
J Clin Gastroenterol; 1998 Sep; 27(2):154-5. PubMed ID: 9754780
[No Abstract] [Full Text] [Related]
24. Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival duration.
Lippman SM; Alberts DS; Slymen DJ; Weiner S; Aristizabal SA; Luditch A; Davis JR; Surwit EA
Cancer; 1988 Jun; 61(12):2571-7. PubMed ID: 3365677
[TBL] [Abstract][Full Text] [Related]
25. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Int J Gynecol Cancer; 2001; 11(4):277-82. PubMed ID: 11520365
[TBL] [Abstract][Full Text] [Related]
26. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
[TBL] [Abstract][Full Text] [Related]
27. Correlation of abdominal ultrasound and computed tomography scans with second- or third-look laparotomy in patients with ovarian carcinoma.
Lund B; Jacobsen K; Rasch L; Jensen F; Olesen K; Feldt-Rasmussen K
Gynecol Oncol; 1990 May; 37(2):279-83. PubMed ID: 2188880
[TBL] [Abstract][Full Text] [Related]
28. A study of serum CASA and CA 125 levels in patients with ovarian carcinoma.
Meisel M; Straube W; Weise J; Burkhardt B
Arch Gynecol Obstet; 1995; 256(1):9-15. PubMed ID: 7726659
[TBL] [Abstract][Full Text] [Related]
29. CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer.
Makar AP; Kristensen GB; Børmer OP; Tropé CG
Gynecol Oncol; 1992 Jun; 45(3):323-8. PubMed ID: 1612511
[TBL] [Abstract][Full Text] [Related]
30. Alpha 1-acid glucoprotein in ovarian cancer with a reference to immunosuppressive acidic protein and cancer antigen 125.
Mogensen O; Mogensen B; Jakobsen A
Cancer; 1989 Nov; 64(9):1867-71. PubMed ID: 2477138
[TBL] [Abstract][Full Text] [Related]
31. The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects.
Bottoni P; Scatena R
Adv Exp Med Biol; 2015; 867():229-44. PubMed ID: 26530369
[TBL] [Abstract][Full Text] [Related]
32. Second-look laparotomy in ovarian cancer.
Creasman WT
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S122-7. PubMed ID: 7835795
[TBL] [Abstract][Full Text] [Related]
33. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma.
Diamandis EP; Scorilas A; Fracchioli S; Van Gramberen M; De Bruijn H; Henrik A; Soosaipillai A; Grass L; Yousef GM; Stenman UH; Massobrio M; Van Der Zee AG; Vergote I; Katsaros D
J Clin Oncol; 2003 Mar; 21(6):1035-43. PubMed ID: 12637468
[TBL] [Abstract][Full Text] [Related]
34. Soluble interleukin-2 receptors and CA 125 in ovarian cancer, a longitudinal and cross-sectional study.
Burch D; Metcalfe S; Gallagher G; al-Azzawi F; Wheeler T
Eur J Gynaecol Oncol; 1994; 15(5):352-8. PubMed ID: 7828604
[No Abstract] [Full Text] [Related]
35. The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.
Alvarez Secord A; Sayer R; Snyder SA; Broadwater G; Rodriguez GC; Berchuck A; Blackwell K
Gynecol Oncol; 2004 Jul; 94(1):74-9. PubMed ID: 15262122
[TBL] [Abstract][Full Text] [Related]
36. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients.
Obermair A; Sevelda P
Acta Obstet Gynecol Scand; 2001 May; 80(5):432-6. PubMed ID: 11328220
[TBL] [Abstract][Full Text] [Related]
37. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
Guo N; Peng Z
J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
[TBL] [Abstract][Full Text] [Related]
38. Use of second-look laparotomy in the management of patients with ovarian epithelial malignancies.
Podczaski ES; Stevens CW; Manetta A; Whitney CW; Larson JE; Mortel R
Gynecol Oncol; 1987 Oct; 28(2):205-14. PubMed ID: 3666578
[TBL] [Abstract][Full Text] [Related]
39. Limitations to the use of the CA-125 antigen level in ovarian cancer.
Markman M
Curr Oncol Rep; 2003 Jul; 5(4):263-4. PubMed ID: 12781066
[No Abstract] [Full Text] [Related]
40. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
Sölétormos G; Duffy MJ; Othman Abu Hassan S; Verheijen RH; Tholander B; Bast RC; Gaarenstroom KN; Sturgeon CM; Bonfrer JM; Petersen PH; Troonen H; CarloTorre G; Kanty Kulpa J; Tuxen MK; Molina R
Int J Gynecol Cancer; 2016 Jan; 26(1):43-51. PubMed ID: 26588231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
